Evidence map›Paper›PMID 42210538›Full record

ArticleJournal of medicinal chemistry2026

Designing Antibiotics with Inherent Resistance to Efflux as a Strategy to Revive Discovery against Multidrug-Resistant Pathogens.

Mark Laws, Charlotte K Hind, Kazi Sharmin Nahar, Melanie Clifford, Caleb Marsh, Taha Al Adhami, Brice Louis, Manming Xu, Saleh O Alyemni, Shozeb Haider and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mark LawsSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Charlotte K HindCountermeasures Development, Evaluation and Preparedness, Public Health Microbiology, UK Health Security Agency, Manor Farm Road, Porton Down, Salisbury SP4 0JG, U.K.ORCID 0000-0002-3763-3106
Kazi Sharmin NaharSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Melanie CliffordCountermeasures Development, Evaluation and Preparedness, Public Health Microbiology, UK Health Security Agency, Manor Farm Road, Porton Down, Salisbury SP4 0JG, U.K.
Caleb MarshCountermeasures Development, Evaluation and Preparedness, Public Health Microbiology, UK Health Security Agency, Manor Farm Road, Porton Down, Salisbury SP4 0JG, U.K.ORCID 0000-0002-0265-0221
Taha Al AdhamiSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Brice LouisSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Manming XuUCL School of Pharmacy, University College London, London WC1N 1AX, U.K.
Saleh O AlyemniUCL School of Pharmacy, University College London, London WC1N 1AX, U.K.
Shozeb HaiderUCL School of Pharmacy, University College London, London WC1N 1AX, U.K.ORCID 0000-0003-2650-2925
Mushtaq HassanSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Nupur GargateSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.
Matthew E WandCountermeasures Development, Evaluation and Preparedness, Public Health Microbiology, UK Health Security Agency, Manor Farm Road, Porton Down, Salisbury SP4 0JG, U.K.
J Mark SuttonSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.ORCID 0000-0002-2288-0446
Khondaker Miraz RahmanSchool of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, U.K.ORCID 0000-0001-8566-8648

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a novel Efflux Resistance Breaker (ERB) strategy for designing antibiotics intrinsically resistant to efflux, using fluoroquinolones as a model class. ERB-modified fluoroquinolones showed enhanced intracellular accumulation and markedly improved antibacterial activity, with up to 512-fold reduction in MIC (MIC

Indexed as

Anti-Bacterial AgentsDrug DesignDrug Resistance, Multiple, BacterialAnimalsMiceMicrobial Sensitivity TestsStructure-Activity RelationshipAnti-Bacterial Agents

Identifiers

PMID42210538
PMCPMC13266999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.